{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:30Z","timestamp":1761059190186},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,15]]},"DOI":"10.2146\/ajhp100181","type":"journal-article","created":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T23:04:40Z","timestamp":1299279880000},"page":"491-498","source":"Crossref","is-referenced-by-count":12,"title":["Ceftaroline: A new broad-spectrum cephalosporin"],"prefix":"10.1093","volume":"68","author":[{"given":"Lauren","family":"Lim","sequence":"first","affiliation":[{"name":"Unity Health Systems, Rochester, NY; at the time of writing she was student, School of Pharmacy and Pharmaceutical Science, State University of New York (SUNY) at Buffalo, Buffalo."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Sutton","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center (URMC), Rochester; at the time of writing she was student, School of Pharmacy and Pharmaceutical Science, SUNY at Buffalo."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Brown","sequence":"additional","affiliation":[{"name":"Schools of Pharmacy and Pharmaceutical Science and Public Health, SUNY at Buffalo, and Infectious Disease Clinical Specialist, Department of Pharmacy, URMC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041105534664100_b1-0680491","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"Klevens","year":"2007","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041105534664100_b2-0680491","unstructured":"Food and Drug Administration. FDA approves Teflaro for bacterial infections. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm231594.htm (accessed 2010 Nov 16)."},{"key":"key\n\t\t\t\t2019041105534664100_b3-0680491","article-title":"Activity of ceftaroline (CPT) against recent Streptococcus pneumoniae (SP) isolates: from the Canadian Bacterial Surveillance Network (CBSN)","author":"Farrell","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b4-0680491","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States","volume":"52","author":"Ge","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"key\n\t\t\t\t2019041105534664100_b5-0680491","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"key\n\t\t\t\t2019041105534664100_b6-0680491","article-title":"Ceftaroline activity tested against organisms causing skin and skin structure infections (SSSI) isolated in USA and European Medical Centers in 2008","author":"Jones"},{"key":"key\n\t\t\t\t2019041105534664100_b7-0680491","article-title":"Activity of ceftaroline vs daptomycin and tigecycline against methicillin-susceptible, methicillin-resistant, and glycopeptide-intermediate Staphyloccus aureus: an experimental rabbit endocarditis study","author":"Jacqueline","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b8-0680491","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1128\/AAC.01021-08","article-title":"In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing","volume":"53","author":"Brown","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"key\n\t\t\t\t2019041105534664100_b9-0680491","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(03)00126-3","article-title":"TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties","volume":"11","author":"Ishikawa","year":"2003","journal-title":"Bioorg Med Chem."},{"key":"key\n\t\t\t\t2019041105534664100_b10-0680491","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/14728214.12.4.511","article-title":"Emerging cephalosporins","volume":"12","author":"Page","year":"2007","journal-title":"Expert Opin Emerg Drugs."},{"key":"key\n\t\t\t\t2019041105534664100_b11-0680491","doi-asserted-by":"crossref","first-page":"9212","DOI":"10.1021\/ja8029448","article-title":"Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics","volume":"130","author":"Villegas-Estrada","year":"2008","journal-title":"J Am Chem Soc."},{"key":"key\n\t\t\t\t2019041105534664100_b12-0680491","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.emc.2008.01.010","article-title":"Community-associated methicillin- resistant Staphylococcus aureus","volume":"26","author":"Wallin","year":"2008","journal-title":"Emerg Med Clin North Am."},{"key":"key\n\t\t\t\t2019041105534664100_b13-0680491","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijantimicag.2008.12.005","article-title":"Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia","volume":"33","author":"Morrissey","year":"2009","journal-title":"Int J Antimicrob Agents."},{"key":"key\n\t\t\t\t2019041105534664100_b14-0680491","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"key\n\t\t\t\t2019041105534664100_b15-0680491","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jac\/dkm150","article-title":"In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes","volume":"60","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"key\n\t\t\t\t2019041105534664100_b16-0680491","article-title":"Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline (CPT)","author":"Hinshaw","year":"2008"},{"key":"key\n\t\t\t\t2019041105534664100_b17-0680491","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC \u03b2-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev."},{"key":"key\n\t\t\t\t2019041105534664100_b18-0680491","article-title":"Bactericidal activity of ceftaroline combined with NXL104 against critical targeted organisms possessing various resistance mechanisms","author":"Castanheira","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b19-0680491","article-title":"Spectrum and activity of ceftaroline combined with NXL104 tested against a challenge collection of pathogens with well characterized resistances","author":"Sader","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b20-0680491","article-title":"In vivo antibacterial efficacy of ceftaroline (cpt) combined with the \u03b2-lactamase inhibitor NXL104 in a murine septicemia model","author":"Levasseur","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b21-0680491","article-title":"Activity of chequerboard combinations of ceftaroline and nxl104 vs \u03b2-lactamase producers","author":"Mushtaq","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b22-0680491","article-title":"Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects","author":"Ge","year":"2006"},{"key":"key\n\t\t\t\t2019041105534664100_b23-0680491","article-title":"The pharmacokinetics and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions","author":"Ge","year":"2006"},{"key":"key\n\t\t\t\t2019041105534664100_b24-0680491","article-title":"A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection in healthy subjects","author":"Riccobene","year":"2008"},{"key":"key\n\t\t\t\t2019041105534664100_b25-0680491","article-title":"Pharmacokinetics (PK) of ceftaroline (PPI0903) in subjects with mild or moderate renal impairment (RI)","author":"Ge","year":"2006"},{"key":"key\n\t\t\t\t2019041105534664100_b26-0680491","article-title":"Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infection (cSSSI)","author":"Ge","year":"2007"},{"key":"key\n\t\t\t\t2019041105534664100_b27-0680491","article-title":"Penetration of ceftaroline (PPI-0903), a new cephalosporin, into lung tissues: measurement of plasma and lung tissue concentrations after a short IV infusion in the rabbit","author":"Jacqueline","year":"2006"},{"key":"key\n\t\t\t\t2019041105534664100_b28-0680491","article-title":"In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903)","author":"Ge","year":"2006"},{"key":"key\n\t\t\t\t2019041105534664100_b29-0680491","article-title":"An open-label pharmacokinetic (PK), safety, and tolerability study of single intravenous (IV) doses of ceftaroline (CPT) in subjects with normal renal function or severe renal impairment","author":"Riccobene","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b30-0680491","article-title":"Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI)","author":"Ge","year":"2007"},{"key":"key\n\t\t\t\t2019041105534664100_b31-0680491","article-title":"An open-label pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis","author":"Riccobene","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b32-0680491","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.50.4.1376-1383.2006","article-title":"Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic- pharmacodynamic target","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"key\n\t\t\t\t2019041105534664100_b33-0680491","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"key\n\t\t\t\t2019041105534664100_b34-0680491","article-title":"CANVAS-1: randomized, double-blinded, phase 3 study (P903\u201306) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI)","author":"Corey","year":"2008"},{"key":"key\n\t\t\t\t2019041105534664100_b35-0680491","article-title":"CANVAS-2: randomized, double-blinded, phase 3 study (P903\u201307) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections","author":"Wilcox","year":"2009"},{"key":"key\n\t\t\t\t2019041105534664100_b36-0680491","unstructured":"ClinicalTrials.gov. Clinical trials of ceftaroline. http:\/\/clinicaltrials.gov\/ct2\/results?term=ceftaroline (accessed 2010 Mar 25)."},{"key":"key\n\t\t\t\t2019041105534664100_b37-0680491","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis."},{"key":"key\n\t\t\t\t2019041105534664100_b38-0680491","volume-title":"Teflaro (ceftaroline fosamil) prescribing information","year":"2010"},{"key":"key\n\t\t\t\t2019041105534664100_b39-0680491","unstructured":"Forest Laboratories. Novexel and Forest Laboratories announce license agreement for NXL104, a novel broad-spectrum beta-lactamase inhibitor. www.frx.com\/news\/PressRelease.aspx?ID=1369192 (accessed 2010 Jan 15)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/6\/491\/28349077\/ajhp0491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T00:34:31Z","timestamp":1560040471000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/6\/491\/5129707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,15]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,3,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100181","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,3,15]]},"published":{"date-parts":[[2011,3,15]]}}}